Thyrocare appoints Dr Ramesh Kinha as COO

Dr Kinha is a seasoned healthcare and diagnostics leader with over 17 years of experience across leading organisations in the diagnostics sector, with deep expertise in laboratory operations and quality systems

Godavari Biorefineries launches US biotech arm to advance novel cancer therapies

The move strengthens GBL’s clinical-stage presence in the United States

Vanda Pharmaceuticals seeks FDA nod for breakthrough psoriasis drug

Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients

Biocon launches its Glucagon-like Peptide-1, Liraglutide, in the Netherlands

Anil Koul joins Mankind Pharma as Group Chief Scientific Officer

More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline

Shilpa Medicare receives initial authorization for Rotigotine transdermal patch from Europe

This is the first approval of a prescription transdermal dosage Form in the European markets from this facility

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines

Denali clinches $275 million royalty deal to power potential breakthrough Hunter Syndrome therapy

Biocon to merge Biocon Biologics in $5.5 billion deal

Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million

Briefs: Sun Pharma and Venus Remedies

Sun Pharma to set up Rs. 3,000 crore greenfield formulations facility in MP